Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

DGDA: No plans to use Gonoshasthaya Kendra’s rapid test kits

Bangladesh authorities currently have no plans to use the kit since the World Health Organization (WHO) has not yet approved it

Update : 27 Apr 2020, 03:18 PM

As the World Health Organization has yet to allow the rapid test kits for testing Covid-19 samples, the Bangladeshi authorities will not use the kits produced by Gonoshasthaya Kendra.

However, the government said that it will continue to support the program since the kit may get approved in the future.

Bangladesh is currently testing coronavirus cases using other test kits.

The government has said that the Gonoshasthaya Kendra has not properly followed production procedures in developing its rapid test kit for coronavirus.

“The rapid kit is not approved by the WHO as its sensitivity is around 30%. It means that the kit will produce a high percentage of false results. As no other countries are using such kits, we have no plans to use it now,” said Major General Mahbubur Rahman, director general of the Directorate General of Drug Administration (DGDA).

Mahbub made the statements while briefing reporters at the Bangladesh Secretariat on Monday.

“China and India started to use them but stopped since they were producing false results,” he added.

Habibur Rahman, additional secretary of the Health Service Division, said: “We have enough stock of other test kits: around 100,000 of them. We have no shortage.”

“The number of tests has also been increasing everyday as many kits are in the pipeline,” he added.

‘Not following due process’

The DG of DGDA said: “We are facilitating the innovation of testing kits by Bangladeshi scientists, and we will continue to do so. But the Gonoshasthaya Kendra is not following due process.”

Gonoshasthaya Kendra authorities recently went to hand over their Covid-19 rapid test kits that to the representatives of Bangabandhu Sheikh Mujib Medical University (BSMMU) and the US Centers for Disease Control and Prevention (CDC) for final approval. However, officials were not present to receive them.

“The steps are - innovate a kit, test its sensitivity, conduct trial runs, do performance evaluation, clear verification of trials, and if the results are satisfactory, then go to production. But the Gonoshasthaya Kendra organized a program to hand over the test kits without doing trial runs and performance evaluation,” said Mahbub.

“As the process has not been completed, we didn’t receive the kits,” he added.

According to the rules, a protocol should be formed by Gonoshasthaya Kendra should jointly establish a protocol with a contract research firm (CRO) mentioning details of the trials, how many trial tests are needed, and how much time is required.  

Bangladesh Medical Research Centre (BMRC) will certify whether the process is okay or not. DGDA would then approve marketing following results of trial tests and evaluation by BMRC. 

The committee for approval is being formed with a renowned scientist, a specialist physician, and two members from DGDA. 

The DG of DGDA said Gonoshasthaya Kendra can work with the International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b) as CRO support, but Gonoshasthaya did not agree to that, saying that icddr,b is closed due to the lockdown.

However, icddr,b is open for conducting any kind of research. “We sent them the names of nine organizations who could provide the support,” Mahbub said.

“Gonoshasthaya Kendra Founder Dr Zafrullah Chowdhury has also been spreading misleading information about us, which not only disrespected us, but also served to create confusion; but we will always remain supportive of innovation,” he added.

He said that discussions and dealings with Gonoshasthaya Kendra regarding the development and production of the test kits have been very transparent.

“Whenever they sought any kind of support we provided it immediately, since we know that we must work together to overcome the pandemic,” he said.

“Despite all our support, we do not know how he [Dr Zafrullah Chowdhury] could accuse us of corruption. In any case, scientist Bijon Kumar Shil, who worked beside him, has cleared us of any accusations of taking bribes,” he added.

“We expect Gonoshasthaya Kendra to be more science based and more courteous towards us,” he added.

Top Brokers